CYTOKINETICS INC — Director's Dealing 2025

Mar 18, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CYTOKINETICS INC (CYTK)
CIK: 0001061983
Period of Report: 2025-03-14

Reporting Person: Malik Fady Ibraham (EVP Research & Development)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-03-14	Common Stock	A	39450	—	Acquired	144844	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-03-14	Incentive Stock Option (Right to Buy)	$44.36	A	2293	Acquired	2035-03-13	Common Stock (2293)	Direct
2025-03-14	Non-Qualified Stock Option (Right to Buy)	$44.36	A	58465	Acquired	2035-03-13	Common Stock (58465)	Direct

Footnotes

F1: Comprised of restricted stock units that convert to shares of common stock on a 1:1 basis upon vesting. 40% of the RSUs will vest on the 1-year anniversary of the date of grant; an additional 40% of the RSUs will vest on the 2-year anniversary of the date of grant; and the final 20% of the RSUs will vest on the 3-year anniversary of the date of grant, in each case subject to Dr. Malik's continued employment with the company on the scheduled vesting date.

F2: Stock options vest in equal monthly installments over 48 months from the date of grant, subject to Dr. Malik's continued employment with the company on the scheduled vesting date.

F3: Stock options vest in equal monthly installments over 48 months from the date of grant, subject to Dr. Malik's continued employment with the company on the scheduled vesting date.